Recurrence of neovascular age-related macular degeneration after cessation of treat and extend regimen

Yuki Hirata1, Akio Oishi1, Yuki Maekawa1, Eiko Tsuiki1, Akira Machida1, Junko Kurihara2 & Takashi Kitaoka1

The appropriate timing of treatment cessation after treat and extend (TAE) regimen for age-related macular degeneration has not been established. This study aimed to investigate the incidence and risk factors of recurrence after cessation of the TAE regimen. We included patients who received and discontinued the TAE regimen, after extension of the treatment interval to ≥ 12 weeks. Forty-nine patients were included in the study. The estimated recurrence rates were 33% at 1 year and 48% at 2 years after treatment cessation, respectively. Good visual acuity at cessation and a large number of injections in the 6 months before cessation were significant risk factors. Higher chances of recurrence were associated with < 0.1 logarithm of the minimum angle of resolution (logMAR) at cessation (P < 0.002). Meanwhile, five patients with visual acuity ≥ 1.0 logMAR at cessation did not show recurrence. Among the 25 recurrences, two lines of vision loss were noted in only two cases after resumed treatment. This study confirmed the importance of the number of injections in reducing recurrence and the association between visual acuity and recurrence. Recurrence is generally well-controlled with resumed treatment.

Age-related macular degeneration (AMD) is the leading cause of blindness, particularly in developed countries1. The disease is classified into neovascular and atrophic forms, with the former characterized by macular neovascularization (MNV)2. MNV induces leakage, bleeding, and scarring, which subsequently impairs vision function. The development of anti-vascular endothelial growth factor (VEGF) therapy has dramatically improved the visual outcome of neovascular AMD (nAMD)3. Anti-VEGF agents are administered in fixed, proactive, or reactive regimens. Among several treatment regimens, treat and extend (TAE) consists of injection and adjustment of the interval depending on the retinal exudative change4. The regimen is widely chosen due to its balanced cost and efficacy on visual function5–7. Meanwhile, anti-VEGF agents are expensive, and the treatment requires frequent injection and hospital visits, which are a major burden for elderly patients and the healthcare system8,9. It is impractical to continue anti-VEGF treatment endlessly in all patients. In fact, the dropout of patients due to socioeconomic or health reasons is not uncommon in clinical practice10. Prolonged anti-VEGF therapy may also be associated with a risk of endophthalmitis and macular atrophy11,12. Drug suspension, if possible, would decrease the burden on patients, the healthcare system, and the risk of complications.

Several reports have described cessation of the TAE regimen and the incidence of subsequent recurrences. In these reports, cessation of treatment was considered when there was no recurrence of exudative changes after the predetermined treatment interval (e.g., 12 or 16 weeks)13–21. However, the timing of treatment cessation may vary depending on the clinical course and the patient's preferences in real world clinical practice. The effect of the last treatment interval cannot be analyzed if all patients quit treatment with the same predetermined interval. To address this issue, we investigated real-world data to elucidate the incidence and risk factors of recurrence in patients with nAMD treated with the TAE regimen and discontinued treatment.

1Department of Ophthalmology and Visual Sciences, Graduate School of Biomedical Sciences, Nagasaki University, Sakamoto 1-7-1, Nagasaki 852-8102, Japan. 2Department of Ophthalmology, Japanese Red Cross Nagasaki Genbaku Hospital, Mori-machi, Nagasaki 852-8511, Japan. *email: akio.oishi@nagasaki-u.ac.jp
Results

Study population. In this study, 78 eyes were included, including 74 cases who met the inclusion criteria in the single eye and the right eyes of 4 bilateral cases. After excluding 26 eyes within the follow-up period of <12 months and three eyes with other macular diseases (two diabetic macular edema and one macular hole), 49 eyes of 49 patients were included and analyzed.

Baseline characteristics and treatment course of patients. Recurrence was observed in 25 patients (51%) at a median of 10.5 months (interquartile range [IQR] 8.1–18.2 months, range 4.4–36.5 months). The mean follow-up time was 34.8 ± 19.8 months (range 12.1–83.8 months). Sixty-four percent of the recurrences developed in the first year, and 20% were identified in the second year after cessation of treatment. Patient characteristics are shown in Table 1 and macular findings on OCT determined as recurrence after cessation are in Table 2.

| Baseline data                        | All (n = 49) | Non-recurrent (n = 24) | Recurrent (n = 25) | P-value |
|--------------------------------------|-------------|-----------------------|-------------------|--------|
| Age, years                           | 72.8 (8.3)  | 77.0 (68.0–80.3)      | 70.0 (65.0–78.0)  | 0.19*  |
| Sex, n (%) Men                       | 31 (63.3)   | 13 (54.2)             | 18 (72.0)         | 0.244† |
| Anti-VEGF at first, n (%) aflibercept| 39 (79.6)   | 18 (75.0)             | 21 (84.0)         | 0.496* |

| MNV type, n (%)                      |             |                      |                   | 0.184† |
|--------------------------------------|-------------|----------------------|------------------|--------|
| Type 1                               | 34 (69.4)   | 17 (70.8)            | 17 (68.0)        |        |
| (PCV)                                | 28 (57.1)   | 15 (62.5)            | 13 (52.0)        |        |
| Type 2                               | 10 (20.4)   | 5 (12.5)             | 7 (28.0)         |        |
| Type 3                               | 5 (10.2)    | 4 (16.7)             | 1 (4.0)          |        |
| PED at baseline, n (%)               | 39 (79.6)   | 20 (83.3)            | 19 (76.0)        | 0.725† |

| Treatment data                       |             |                      |                   |        |
|--------------------------------------|-------------|----------------------|------------------|--------|
| Treatment period, months             | 18.8 (12.3–26.2) | 20.9 (16.5–28.4)   | 15.8 (10.6–20.9) | 0.008* |
| Total injections, n                   | 10 (8–12)   | 11.5 (9.0–13.3)      | 8.0 (7.0–11.0)   | 0.004* |
| Injections for a dry macula in loading phase, n | 1 (1–1) | 1.0 (1.0–1.3) | 1.0 (1.0–2.0) | 0.959* |
| Injections in the 6 months before cessation | 3 (2–3) | 2 (2–3) | 3 (2–3) | 0.002* |
| Injections in the 1 year before cessation | 5.4–6   | 5 (4–6) | 6 (5–6) | 0.119* |
| Last treatment interval, weeks       | 13.6 (12–16) | 15.4 (13.4–16.0)  | 12.0 (12.0–14.0) | 0.003* |
| Dry macula period before cessation, months | 16.3 (12.2–21.7) | 19.3 (15.8–26.3) | 12.8 (9.6–18.8) | 0.004* |

| OCT characteristic at cessation, n, (%) |             |                      |                   |        |
|------------------------------------------|-------------|----------------------|------------------|--------|
| PED                                      |             |                      |                  |        |
| Serous                                   | 0           | 0                    | 0                |        |
| Fibrovascular                            | 19 (38.8)   | 11 (45.8)            | 8 (32.0)         | 0.387† |
| Atrophy                                  | 15 (30.6)   | 9 (37.5)             | 6 (24.0)         | 0.364† |
| BCVA, logMAR                             |             |                      |                  |        |
| Baseline                                 | 0.52 (0.38–0.86) | 0.40 (0.30–0.70)   | 0.40 (0.30–0.70) | 0.227† |
| Last injection                           | 0.26 (0.16–0.82) | 0.16 (0.05–0.40)  | 0.16 (0.05–0.40) | 0.080† |
| Recurrence                               | 0.22 (0.05–0.50) | ~                    | ~                | ~      |
| After retreatment                        | 0.16 (0.00–0.40) | ~                    | ~                | ~      |
| Last visit                               | 0.30 (0.16–0.52) | 0.10 (0.00–0.52)  | 0.10 (0.00–0.52) | 0.165† |

Table 1. Characteristics of patients with neovascular age-related macular degeneration with and without recurrence after cessation of treatment. Data are presented as median (Interquartile range), unless otherwise indicated. BCVA, best-corrected visual acuity; IRF, intraretinal fluid; logMAR, logarithm of the minimum angle of resolution; MNV, macular neovascularization; OCT, optical coherence tomography; PED, pigment epithelial detachment; SRF, subretinal fluid; VEGF, vascular endothelial growth factor. *Mann–Whitney U test. †A chi-square test.
The recurrence rate was 89% in patients with a last treatment interval < 13 weeks. The distribution of the last treatment interval and the number of injections are shown in Fig. 1. The degree of improvement with treatment was similar between non-recurrent group and recurrent group (median −1.8 logMAR vs. −2.3 logMAR, \( \text{P} = 0.24 \)). Four patients (17%) had a visual loss of ≥ 0.2 logMAR due to recurrence. Twelve patients stopped treatment again and showed no recurrence until the last visit. Ten patients continued treatment with TAE or a fixed dosing. One patient dropped out, one was transferred to another clinic, and one died. The mean follow-up period after recurrence was 34.3 ± 14.9 months. There were no significant differences in visual acuity at cessation, at recurrence, and at the last visit (0.16 logMAR, 0.22 logMAR, 0.1 logMAR, respectively) (\( \text{P} = 0.84 \)).

**Clinical courses after the recurrences.** After recurrence, the patients were re-treated with anti-VEGF agents, photodynamic therapy, and/or retinal photocoagulation. Only two patients (8%) had a visual acuity loss of ≥ 0.2 logMAR due to recurrence. Twelve patients stopped treatment again and showed no recurrence until the last visit. Ten patients continued treatment with TAE or a fixed dosing. One patient dropped out, one was transferred to another clinic, and one died. The mean follow-up period after recurrence was 34.3 ± 14.9 months. There were no significant differences in visual acuity at cessation, at recurrence, and at the last visit (0.16 logMAR, 0.22 logMAR, 0.1 logMAR, respectively) (\( \text{P} = 0.84 \)).

**Course of the non-recurrent group.** The median follow-up time in the non-recurrent group was 18.8 months (IQR 13.0–24.5 months). The median BCVA at the last visit was 0.3 logMAR and was not significantly different from that in the recurrent group (\( \text{P} = 0.37 \)). Four patients (17%) had a visual loss of ≥ 0.2 logMAR from cessation to the last visit.

**Discussion**

We investigated the incidence and risk factors for recurrence after treatment cessation. It was found that 51% of patients with nAMD experienced recurrence at a median of 10.5 months after cessation of TAE. The non-recurrent group had a longer treatment period, longer last treatment interval, longer dry period, and a larger number of injections before cessation. BCVA at cessation and the number of injections in 6 months before cessation were associated with the risk of recurrence (Table 3). BCVA < 0.1 logMAR (\( \text{P} = 0.02 \)) at cessation, and the number of injections in the 6 months before cessation of ≥ 3 (\( \text{P} = 0.073 \)) were associated with recurrence risk. (Fig. 2b, c) These thresholds were determined using receiver operating characteristic (ROC) curves. None of the factors correlated with the time to recurrence.

There are several reports on the cessation of the TAE regimen and subsequent recurrences (Table 4)\(^{15–21}\). Adrean et al.\(^{13}\) proposed Treat, Extend, and Stop protocol, in which continuous treatment is posed after two consecutive injections by extending the treatment interval to 12 weeks with careful TAE. The recurrence rate was 16% in 1 year. Munk et al.\(^{14}\) stopped treatment after three 16-week-interval injections and reported a recurrence rate of 15% within 9 months. Other studies showed a 38–53% recurrence rate in 1 year\(^{15,18–21}\).

Among the previously reported predictive factors for recurrence, low visual acuity at treatment cessation was also associated with fewer recurrences in our study. The association between poor visual acuity and fewer recurrences was explained, such that, eyes with reduced visual acuity also had retinal atrophy, which had lower risk of recurrence because the activity of their MNV is already withered. In fact, all five patients with BCVA worse than 1.0 logMAR at cessation and who did not show recurrence, had macular atrophy. Additionally, good visual acuity (VA) was a risk factor for recurrence in the present study. We considered that patients with good VA and

| Fluid | 4 |
| SRF + IRF + PED | 1 |
| SRF + PED | 2 |
| SRF | 15 |
| IRF | 2 |
| PED | 1 |
| **Total** | **n**=25 |

**Table 2.** Macular findings on OCT determined at recurrence after cessation. IRF, intraretinal fluid; OCT, optical coherence tomography; PED, pigment epithelial detachment; SRF, subretinal fluid;
good response to treatment tend to stop treatment early and the insufficient number of injections lead recurrence. However, this was not the case because there was no correlation between VA and the treatment period or number of injections. Atrophy may be one reason; eyes with good vision generally have no atrophy and showed more recurrences. However, it remains still unclear why good VA is associated with a higher incidence of recurrence.

In the present study, 80% of the patients in the recurrent group had a last treatment interval of 13 weeks or less, suggesting that the last treatment interval of 12 weeks was too short. Meanwhile, no recurrence within 12–16 weeks treatment interval is a common criterion for treatment cessation, and treatment interval seemed to

Figure 1. Distribution of (a) last treatment interval, (b) total number of injections and (c) number of injections in the 6 months before cessation in patients with neovascular age-related macular degeneration who stopped treat and extend regimen of anti-vascular endothelial growth factor therapy. Recurrence was frequent in patients with last treatment interval of 12 weeks, total number of injections of less than 12 and number of injections in the 6 months before cessation of 3 or more.
have little effect on the recurrence rate in previous studies (Table 4). In addition, the median time prior to recurrence in the present study was 8.5 months, and the shortest case was 4.4 months. Thus, the treatment interval could be safely extended to 16 weeks in cases with a last treatment interval of 13 weeks or less. It is unreasonable to consider that most of these subsequent recurrences were prevented if a few additional injections were administered in these cases. In fact, multivariate analysis suggests that the last treatment interval is a confounding factor but is not an independent factor for the risk of recurrence.

The large number of injections in the 6 months before cessation was a significant risk factor. A larger number of injections in the 6 months before cessation means that treatment interval was extended at a high pace and treatment was discontinued after a short observation. The result indicates that even in patients with a long last

Table 3. Cox proportional hazard analysis of risk factors on recurrence after cessation of treatment in patients with neovascular age-related macular degeneration. BCVA = best-corrected visual acuity.

|                        | Hazard ratio | Lower 95% CI | Upper 95% CI | P value |
|------------------------|--------------|--------------|--------------|---------|
| BCVA at a last injection| 0.135        | 0.024        | 0.756        | 0.024   |
| Number of injections in the 6 months before cessation | 2.047 | 1.252 | 3.349 | 0.004 |

Figure 2. Kaplan–Meier survival curves of recurrence after the cessation of treatment in patients with age-related macular degeneration. (a) The estimated recurrence rate was 33% at 12 months and 48% at 24 months, respectively. Patients with (b) best corrected visual acuity (BCVA) &lt; 0.1 logMAR at cessation and (c) number of injections in the 6 months before cessation ≥ 3 had a higher chance of recurrences.
Here, we report the incidence and clinical course of recurrence after cessation of the TAE regimen in patients with nAMD. One-third of the patients experienced recurrence within 1 year after cessation of treatment, but overall, recurrence was observed in half of the patients thereafter. Recurrence was more frequent in patients with poor vision.

The present study has several limitations, including its retrospective design and relatively small sample size. We did not define a pachychoroid. The decision to discontinue treatment was at the physician’s discretion. The studied patients may have been biased toward those with a good course and do not reflect the total AMD cohort. Treatment cessation can be relatively safe in these patients if continuous monitoring is performed.

### Methods

#### Study design.
This was a multicenter, retrospective study. The study design was approved by the Institutional Review Board of Nagasaki University and the Japanese Red Cross Nagasaki Genbaku Hospital, and all study conduct adhered to the tenets of the Declaration of Helsinki. The requirement for written informed consent was waived by the ethics committee, given the retrospective nature of the study. Instead, patients were allowed “opt-out” consent.

#### Patient selection and intervention.
Patients with treatment-naive nAMD receiving intravitreal injections of ranibizumab or aflibercept under a TAE regimen between January 2015 and December 2021 were iden-
tified in our database at the Department of Ophthalmology at Nagasaki University Hospital and Japanese Red Cross Nagasaki Genbaku Hospital.

We included patients who stopped continuous treatment after the treatment interval was extended to ≥12 weeks. Participants were excluded from the study if they were followed up for less than 12 months after the last injection or had other macular or optic nerve diseases. If both eyes met the inclusion criteria, the right eye was selected and studied.

At baseline, participants underwent a comprehensive ophthalmic examination. BCVA was measured using LogMAR. The diagnosis of AMD subtype, e.g., type 1 MNV with or without polypoidal lesions, type 2 MNV, type 3 MNV, was made based on fundoscopy, fundus photography, retinal angiography (fluorescein and indocyanine green), spectral-domain OCT (SD-OCT, Spectralis HRA + OCT instrument, Heidelberg Engineering GmbH, Heidelberg, Germany), and OCT angiography (Angio Vue, OptoVue Inc., Freemont, CA, USA). Retinal angiography was not performed when the patient had a history of drug allergy, active asthma, or renal dysfunction.

All patients initially received three monthly anti-VEGF injections. Thereafter, treatment intervals were extended or shortened at the discretion of the treating physician depending on the retinal exudative change: new retinal hemorrhage, presence of intraretinal and/or subretinal fluid, or enlargement of pigment epithelial detachment (PED) on SD-OCT. In principle, the treatment interval was extended by one or two weeks when there was no sign of exudation and shortened by two weeks or more when exudative changes were noted. When the treatment interval was extended to longer than eight weeks, patients were instructed to visit local ophthalmologists in between. Only patients determined to have no intra or sub-retinal fluid in the macula and stopped treatment were included in the study. Recurrence was defined as the presence of any intra or sub-retinal fluid after cessation. In cases of recurrence, anti-VEGF injections were resumed. The date of recurrence was determined based on the patient’s medical history. When the patient was asymptomatic, we assumed that recurrence developed at the time of when the fluid was confirmed on OCT images.

**Outcomes.** The primary outcome measure was the incidence of post-cessation recurrence. Secondary outcome measures included the effect of BCVA, total treatment period, number of injections, last treatment interval, dry period, and OCT parameters before the cessation of the risk and timing of recurrence. “Dry period” was defined as a non-recurrent period without retinal exudative changes in the macula.

**Statistical Analysis.** All statistical analyses were performed using EZR (Saitama Medical Center, Jichi Medical University, Saitama, Japan), a graphical user interface for R (The R Foundation for Statistical Computing, Vienna, Austria). More precisely, it is a modified version of the R commander designed to add statistical functions frequently used in biostatistics. Significance tests for continuous variables were performed using the Mann–Whitney U test. Wilcoxon’s signed-rank test was used to compare changes in BCVA. The chi-square test was used to analyze nominal variables. The proportion and time to recurrence were analyzed using Kaplan–Meier survival analysis. The correlation between various parameters was tested using Spearman’s rank correlation coefficient. Cox proportional hazard regression analysis was performed to estimate the hazard ratio for recurrences using univariate and multivariate analyses, number of injections in the 6 months before cessation, and BCVA at cessation. The selection of a priori variables was based on the results of univariate analyses and clinical perspectives. Statistical significance was set at $p < 0.05$.

**Data availability** All the relevant data are presented in the manuscript. The datasets generated and analyzed during the current study are available from the corresponding author upon reasonable request.

Received: 1 July 2022; Accepted: 24 August 2022
Published online: 30 August 2022

**References**

1. Flaxman, S. R. et al. Global causes of blindness and distance vision impairment 1990–2020: A systematic review and meta-analysis. *Lancet Glob. Health* 5, e1221–e1234 (2017).
2. Spaide, R. F. et al. Consensus nomenclature for reporting neovascular age-related macular degeneration data: Consensus on neovascular age-related macular degeneration nomenclature study group. *Ophthalmology* 127, 616–636 (2020).
3. Heier, J. S. et al. Intravitreal aflibercept (VEGF Trap-eye) in wet age-related macular degeneration. *Ophthalmology* 119, 2537–2548 (2012).
4. Berg, K., Pedersen, T. R., Sandvik, L. & Bragadóttir, R. Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol. *Ophthalmology* 122, 146–152 (2015).
5. Gillies, M. C. et al. Long-term outcomes of treatment of neovascular age-related macular degeneration: Data from an observational study. *Ophthalmology* 122, 1837–1845 (2015).
6. Traire, P. G., Pfister, I. B., Zandi, S., Spindler, J. & Garweg, J. G. Long-term outcome of intravitreal aflibercept treatment for neovascular age-related macular degeneration using a “treat-and-extend” regimen. *Ophthalmol. Retina* 3, 393–399 (2019).
7. Singh, R. P., Stone, T. W., Hahn, P. GLOBAL TRENDS in Retina (American, IL, 2019) Society of retina specialist Glob. Trends Retin. Surv. Chicago.
8. Kim, S., Park, S. J., Byun, S. J., Park, K. H. & Suh, H. S. Incremental economic burden associated with exudative age-related macular degeneration: a population-based study. *BMC Health Serv. Res.* 19, 828 (2019).
9. Cruess, A. E. et al. Economic burden of bilateral neovascular age-related macular degeneration: Multi-country observational study. *Pharmacoconomics* 26, 57–73 (2008).
10. Oishi, A. et al. Remission and dropout rate of anti-VEGF therapy for age-related macular degeneration. *Eur. J. Ophthalmol.* 21, 777–782 (2011).
11. Gemenetzii, M., Lottery, A. J. & Patel, P. J. Risk of geographic atrophy in age-related macular degeneration patients treated with intravitreal anti-VEGF agents. *Eye (Lond)* 31, 1–9 (2017).
12. Daien, V. et al. Incidence and outcomes of infectious and noninfectious endophthalmitis after intravitreal injections for age-related macular degeneration. *Ophthalmology* **125**, 66–74 (2018).
13. Adrean, S. D., Chahi, S., Grant, S. & Pirouz, A. Recurrence rate of choroidal neovascularization in neovascular age-related macular degeneration managed with a treat-extend-stop protocol. *Ophthalmol. Retina* **2**, 225–230 (2018).
14. Munk, M. R. et al. The impact of the vitreomacular interface in neovascular age-related macular degeneration in a treat-and-extend regimen with exit strategy. *Ophthalmol. Retina* **2**, 288–294 (2018).
15. Nguyen, V. et al. Outcomes of suspending VEGF inhibitors for neovascular age-related macular degeneration when lesions have been inactive for 3 months. *Ophthalmol. Retina* **3**, 623–628 (2019).
16. Jaggi, D. et al. Aflibercept for age-related macular degeneration: 4-year outcomes of a ‘treat-and-extend’ regimen with exit-strategy. *Br. J. Ophthalmol.* **106**, 1–5 (2022).
17. Kinoshita, T., Mori, J., Hatanaka, A., Shimizu, M. & Imaizumi, H. Visual outcome and treatment frequency of anti-VEGF therapy using the treat-and-extend and treatment cessation regimen for exudative age-related macular degeneration and pachychoroid neovascularopathy. *Clin. Ophthalmol.* **15**, 4405–4418 (2021).
18. Obana, A. et al. Outcomes following the use of treat-and-extend aflibercept therapy for exudative age-related macular degeneration in a single site. *Jpn. Ophthalmol. Soc.** **125**, 1055–1066 (2021).
19. Aslanis, S., Amrén, U., Lindberg, C. & Epstein, D. Recurrent neovascular age-related macular degeneration after discontinuation of vascular endothelial growth factor inhibitors managed in a treat-and-extend regimen. *Ophthalmol. Retina* **6**, 15–20 (2022).
20. Garweg, J. G. et al. Continued anti-VEGF treatment does not prevent recurrences in eyes with stable neovascular age-related macular degeneration using a treat-and-extend regimen: A retrospective case series. *Eye (Lond)* **36**, 862–868 (2022).
21. Matsubara, H. et al. Effects of suspension of anti-vascular endothelial growth factor treatment for neovascular age-related macular degeneration in clinical setting. *Graefes Arch. Clin. Exp. Ophthalmol.* **260**, 1867–1876 (2022).
22. Kanda, Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. *Bone Marrow Transplant.* **48**, 452–458 (2013).

**Acknowledgements**
This study was supported by a grant-in-aid for scientific research (No. 22K09793) from the Japan Society for the Promotion of Science, Tokyo, Japan. A.O. received personal fees from Bayer (Tokyo, Japan), Santen (Tokyo, Japan), Novartis (Tokyo, Japan), Senju (Tokyo, Japan), and Chugai (Tokyo, Japan). Y.M. received personal fees from Novartis Pharma (Tokyo, Japan). Tsuiki Eiko received personal fees from Bayer Pharmaceutical (Tokyo, Japan), Novartis Pharma (Tokyo, Japan), and ALCON JAPAN (Tokyo, Japan). T.K. received fees from Bayer Pharmaceutical (Tokyo, Japan), Santen Pharmaceutical (Tokyo, Japan), Novartis Pharma (Tokyo, Japan), Senju Pharmaceutical (Tokyo, Japan), ALCON JAPAN (Tokyo, Japan), and Kowa Pharmaceutical (Tokyo, Japan).

**Author contributions**
Y.H. and A.O. designed this study. All authors contributed to the data collection. Y.H. and A.O. analyzed and interpreted the data. Y.H and A.O. wrote the first draft, and the other authors revised the manuscript. All authors reviewed and approved the final version of the manuscript.

**Competing interests**
The authors declare no competing interests.

**Additional information**
Correspondence and requests for materials should be addressed to A.O.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022